Corvus announces new interim data from Phase 1 trial of soquelitinib

Corvus Pharmaceuticals (CRVS) announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data includes 28-day follow up results for all patients in cohort 3 and continues to show earlier and deeper responses in cohort 3 compared to cohorts 1 and 2. Overall, data from cohorts 1-3 of the trial have demonstrated a favorable safety and efficacy profile, including a statistically significant improvement in Eczema Area and Severity Index score for the soquelitinib treated patients compared to placebo at day 28. Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2; All three cohorts show separation from placebo with statistically significant difference from placebo at day 28; Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8; Enrollment initiated in extension cohort study exploring the same cohort 3 dose for a longer 8-week treatment period